At Cytek^™, we are focused on accelerating the adoption of flow cytometry for one simple reason: to fuel scientific discovery.

We have leveraged our highly experienced, best-in-the-business team to bring forth an innovative new class of flow cytometry solutions. These solutions deliver deep biological insights at an affordable price, provide high-end capabilities, and bring simplified workflows to more researchers than ever before.

As a Company, we seek to maintain high ethical standards and a culture that values honesty, integrity and transparency in all that we do.

Company decisions are driven by what is right for scientific discovery and customer support. We are committed to our employees, to the environment in which we live and to the communities we serve worldwide.

Wenbin Jiang Ph.D.

Dr. Jiang is a co-founder of Cytek Biosciences, Inc. and a seasoned entrepreneur and inventor. E2O communications was the first company he cofounded in late 1990s, which was acquired by JDS Uniphase in 2004. He is an inventor of more than 90 US patents and an author of 4 book chapters and more than 50 peer reviewed technical papers.

Xin Huang MD Ph.D.

Dr. Xin Huang received his MD from Peking Union Medical College and PhD in Pharmacology and Molecular Sciences from School of Medicine, Johns Hopkins University. He then worked at Boston Consulting Group before he started his VC career in Omaha Capital. In 2012 he joined Cowin Venture and led the firm’s business in Healthcare sector. He has invested about 40 early stage healthcare start-ups in both China and the US during the past several years.

Ming Yan Ph.D.

Dr. Yan is a co-founder of Cytek Biosciences, Inc. with over 20 years of R&D experience in leadership and innovation. Prior to Cytek^™, Dr. Yan held research and development positions at AT&T Bell Laboratories, Lawrence Livermore National Labs and BD Biosciences. He is one of the thought-leaders in flow cytometry instrumentation and standardization. Dr. Yan has published several research papers relating to laser spectroscopy and cell analysis in top peer-reviewed journals. He has over a dozen patents and patent pending applications for his innovations.

Jack Ball

Jack Ball is CEO and a board member at Solulink Inc. He is President of Tyball Associates, LLC. In addition, he serves on the board of directors of Aquaro Histology, Carterra, Celsee Diagnostics, Cytek Biosciences Inc., NanoCellect Inc. and Swift Bioscience. Most recently he was CCO at Accuri Cytometers, which was sold to Becton Dickinson in March 2011. Prior to Accuri Cytometers, he was CEO of Amnis Corporation, and has also served as CCO for Molecular Probes, Inc. Prior to that he was with Orchid Biosciences as Sr. VP and General Manager and with Amersham Pharmacia Biotech Inc., where he rose to President for North Amercia.

Feng Deng

Mr. Feng Deng founded Northern Light Venture Capital (NLVC) in 2005. He has led and backed nearly 200 companies, focusing on 4 main sectors: TMT (technology, media and telecom), clean technology, healthcare and consumer. Prior to NLVC, Feng was a co-founder of NetScreen Technologies, which went public on NASDAQ and was later acquired by Juniper Networks in 2004 for US$ 4.2 billion. Feng is recipient of Ernst & Young Entrepreneur of the Year (2002) and CRN Innovator of the Year (2003) awards. He has extensive technical and managerial experiences in computer, communication and data networking industries. Feng holds BS and MS degrees in electrical engineering from Tsinghua University, a MS degree in computer engineering from the University of Southern California, and a MBA degree from the Wharton School, University of Pennsylvania. He also holds numerous patents of invention in computer system architecture and IC design.

Dr. Yu Fang

Dr. Francine Fang joined 3E Bioventures as partner in May 2015. Prior to 3E Bioventures, Francine worked at Fidelity Growth Partners Asia (FGPA) as venture partner from 2014-2015. She led the investment transactions of Eyebright and Cytoville (Cytek). From 1998 to 2007, Francine worked at Clontech and BD Biosciences as a group leader in R&D for near 10 years in US. She led the assay development for high content screening in BioImaging group at BD Biosciences in San Jose. Before BD acquisition she led the cell biology group at Clontech for the commercialization of multi-color fluorescent proteins and signal transduction product. From 1996 to 1997, Francine worked as a postdoctor in Physiology at University of Medicine and Dentistry of New Jersey. She got Postdoctoral Fellowship from American Heart Association. Francine has Ph.D. degree in Physiology and Neuroscience at University of Medicine and Dentistry of New Jersey and M.D. degree in Medicine at Capital Institute of Medicine in Beijing China.

Dr. Allen Poirson

Dr. Poirson is an experienced life science executive and entrepreneur. Currently a Partner at Mighty Capital, he previously served as CEO and Chair of Sony Biotechnology. Dr. Poirson's domain expertise includes analytic instruments, computational biotechnology, medical devices, in vitro diagnostics, chemistry, and software. Allen has formal scientific training in neuroscience and has held research positions at Howard Hughes Medical Institute and NASA. Dr. Poirson obtained his PhD from Stanford.

Zheng Yuan

Mr. Yuan Zheng Director and CEO. Worked in Chinese Academy of Preventive Medicine; Founder and General Manager of Former Shanghai Moore Biotech Co., Ltd.; Founder of KMC in 2005.

Diether J. Recktenwald Ph.D.

Bob Hoffman

Holden Maecker Ph.D.

Fred Preffer Ph.D.

Dr. rer. nat. Andreas Radbruch

Dr. Bill Telford